enGene Holdings Inc. (NASDAQ:ENGN) Stock Holdings Increased by Point72 Asset Management L.P.

Point72 Asset Management L.P. raised its stake in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) by 84.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,224,797 shares of the company's stock after acquiring an additional 561,797 shares during the period. Point72 Asset Management L.P. owned 2.77% of enGene worth $8,145,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Vontobel Holding Ltd. bought a new stake in shares of enGene in the 4th quarter worth approximately $69,000. Jane Street Group LLC acquired a new stake in enGene in the fourth quarter worth $93,000. Cubist Systematic Strategies LLC lifted its stake in enGene by 15.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock valued at $102,000 after buying an additional 2,080 shares during the last quarter. Corton Capital Inc. bought a new stake in enGene in the 4th quarter valued at about $157,000. Finally, Orbimed Advisors LLC bought a new stake in shares of enGene during the fourth quarter valued at approximately $6,120,000. 64.16% of the stock is owned by institutional investors.

enGene Price Performance

Shares of enGene stock traded down $0.09 during trading on Friday, hitting $4.20. The stock had a trading volume of 19,187 shares, compared to its average volume of 87,352. The business has a fifty day moving average of $4.09 and a two-hundred day moving average of $5.97. enGene Holdings Inc. has a fifty-two week low of $2.65 and a fifty-two week high of $13.00. The firm has a market cap of $214.11 million, a P/E ratio of -7.24 and a beta of -0.36. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ENGN. JMP Securities reiterated a "market outperform" rating and set a $18.00 price target on shares of enGene in a research report on Tuesday, April 29th. Piper Sandler initiated coverage on shares of enGene in a report on Tuesday, February 18th. They issued an "overweight" rating and a $26.00 price objective for the company. Morgan Stanley decreased their target price on shares of enGene from $37.00 to $34.00 and set an "overweight" rating for the company in a research report on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and set a $25.00 target price on shares of enGene in a research note on Tuesday, March 11th. Finally, UBS Group downgraded shares of enGene from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $34.00 to $7.00 in a research report on Friday, February 14th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $23.29.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.